Sorrento Therapeutics Inc. (SRNE) News
Filter SRNE News Items
SRNE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SRNE News Highlights
- For SRNE, its 30 day story count is now at 20.
- Over the past 25 days, the trend for SRNE's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- The most mentioned tickers in articles about SRNE are DRUG, SCLX and ALTO.
Latest SRNE News From Around the Web
Below are the latest news stories about SORRENTO THERAPEUTICS INC that investors may wish to consider to help them evaluate SRNE as an investment opportunity.
Scilex Holding Company announces the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain managementELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The U.S. oral migraine drug market size is estimated to be $1.8 billion in 2022.2There is strong evidence for the use of NSAIDs as a first-line treatment for migraine. Celecoxib is in the same class of agents, is fast acting, and has the potential to have the lowest GI side effects of all NSAIDs.3Strong re-launch commercialization efforts |
The $75 Million Reason Sorrento (SRNE) Stock Is Moving TodaySRNE stock is moving this morning after soaring about 25% yesterday. |
Alphabet Layoffs 2023: What to Know About the Latest Google Job CutsAlphabet (GOOGL,GOOG) layoffs are worth checking on Wednesday as recent reports claim Google job cuts are coming to Ireland. |
Meta Platforms Layoffs 2023: Are More Facebook Job Cuts Coming?Meta Platforms (META) layoffs are a hot topic on Wednesday as reports spread that the Facebook parent company is planning more job cuts. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe're starting off the day with a breakdown of the biggest pre-market stock movers traders need to watch on Wednesday morning! |
Why Sorrento Therapeutics Stock Crashed TodayWhat goes up usually comes down, and that's exactly what happened with Sorrento Therapeutics (NASDAQ: SRNE) today. Shares of Sorrento were crashing 30.4% as of 3:38 p.m. ET on Wednesday after soaring more than 60% on Tuesday. Assuming this decision is finalized, Sorrento will be able to continue normal business operations during its bankruptcy process. |
Bankrupt Sorrento Therapeutics Secures Court Approval for $75M FinancingSorrento Therapeutics Inc (NASDAQ: SRNE) announced that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of Sorrento's $75 million debtor-in-possession financing from JMB Capital Partners. The financing will provide Sorrento with immediate liquidity to continue operating its business as usual during its chapter 11 case. A hearing for final financing approval is currently set for March 29, 2023. Related: Sorrento Therapeutics Stock Nosedives After Filing Bankr |
How to Find Strong Medical Stocks Slated for Positive Earnings SurprisesWhy investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates. |
Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 CaseSorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of Sorrento's $75 million debtor-in-possession financing from JMB Capital Partners, in connection with Sorrento's chapter 11 case, which was filed on February 13, 2023. |
Why Shares of Sorrento Therapeutics Are Up TodayShares of Sorrento Therapeutics (NASDAQ: SRNE) were up 25.8% Tuesday afternoon, after being up as much as 51.6% earlier in the day. The biopharmaceutical company makes therapies to treat cancer, autoimmune disorders, inflammatory conditions, and viral and neurodegenerative diseases. The stock, which plummeted last week after the company said it was filing Chapter 11 bankruptcy proceedings, bounced back after the company clarified that it was protecting Scilex regarding the proceedings. |